EGFR and non-small cell lung carcinoma: Somatic mutations of EGFR tyrosine kinase in non-small cell lung cancer (NSCLC) have been shown to increase kinase activity and to be associated with hypersensitivity to gefitinib, a selective EGFR tyrosine kinase inhibitor (EGFR-TKI) (10,11).